All In Biotech

Drug Trial Radar · NCT06394232

Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

A Phase 1/2a Multi-Center, Dose-Escalation Study to Evaluate the Safety & Efficacy of Eyecyte-RPE™ When Administered as a Single-dose Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Jun 4, 2024

Primary completion

Apr 2025

Study completion Dec 2030

Sponsor

Lead sponsor
Eyestem Research Pvt. Ltd.Industry
Sponsor type
Industry
First posted
May 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD). The main questions it aims to answer are: * Safety and tolerability of the novel stem cell formulation * Potential efficacy of the novel stem cell formulation Participants will receive a single subretinal injection in their study eye and followed up for safety. This is an India only study and the product is developed indigenously.

Conditions

  • Retinal Disease
  • Macular Degeneration
  • Age-Related Macular Degeneration
  • Geographic Atrophy
  • Eye Diseases

Interventions

  • Eyecyte-RPE™Drug

    Eyecyte-RPE™ is a suspension of hiPSCs (human induced Pluripotent Stem Cells) derived Retinal Pigment Epithelial Cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Fundus Autofluorescence-Time frame: Upto 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Shri Ganapati Netralaya

    Jālna, Maharashtra, India · Recruiting

  • All India Institute of Medical Sciences

    Delhi, New Delhi, India · Recruiting

  • L V Prasad Eye Institute

    Hyderabad, Telangana, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.